Loading
Bowel cancer is rising in people under 50, for reasons that are still not understood, and it is usually found late because neither patients nor doctors expect it. Treatment is the same as in older adults and works as well stage for stage; the changes are earlier screening, genetic testing for everyone diagnosed young, and attention to fertility, work and family.
Early-onset colorectal cancer is defined by age under 50 at diagnosis. Birth-cohort analyses (Siegel and colleagues, 2017) showed that people born around 1990 have double the colon cancer risk and four times the rectal cancer risk of those born around 1950 at the same age, a rise seen across high-income countries and attributed to diet, obesity, antibiotics, the microbiome and other early-life exposures without any one cause proven; a colibactin mutational signature from pks-positive Escherichia coli acquired in childhood is enriched in early-onset tumours (Nature 2025). About one in six patients diagnosed under 50 carries a germline cancer-predisposition variant, half of them Lynch syndrome, so multigene germline testing is recommended for everyone in this group.
Most early-onset tumours are left-sided or rectal, microsatellite-stable and diagnosed at stage III or IV after months of rectal bleeding, iron deficiency or change in bowel habit that was attributed to haemorrhoids or irritable bowel. Stage for stage, outcomes are similar to older adults, and treatment follows the same pathways: surgery and stage-based adjuvant chemotherapy, total neoadjuvant therapy or organ preservation for rectal tumours, and genotype-directed therapy for metastatic disease. Young patients receive more intensive chemotherapy without evidence that it helps them more.
The policy response has been earlier screening: the American Cancer Society lowered the starting age for average-risk adults from 50 to 45 in 2018 and the US Preventive Services Task Force followed in 2021; European programmes are debating the same step, and polygenic risk scores may set individual starting ages. For patients, the distinct needs are fertility preservation before pelvic radiotherapy and oxaliplatin, sexual and stoma counselling, financial and employment support, and enrolment in the cohort studies trying to explain the rise.
Roughly one in ten colorectal cancers in high-income countries is now diagnosed before 50, and incidence in this age group has risen by about 2 percent a year in the United States since the mid-1990s while falling in older adults; most are left-sided or rectal and diagnosed at a later stage.
Right-sided tumours behave differently from left-sided and rectal ones; the colon drains along its mesenteric vessels, the rectum into the mesorectum and pelvic side wall.
Same organ: Colon cancer (adenocarcinoma of the colon), Micropapillary adenocarcinoma of the colon and rectum, Adenoma-like adenocarcinoma of the colon and rectum, Lynch syndrome-associated colorectal cancer, Familial adenomatous polyposis-associated colorectal cancer, Mucinous adenocarcinoma of the colon and rectum, Signet ring cell carcinoma of the colon and rectum, Medullary carcinoma of the colon, Serrated adenocarcinoma of the colon and rectum, Peritoneal mesothelioma, Colorectal cancer, Rectal cancer, Mismatch-repair deficient (MSI-high) colorectal cancer, BRAF V600E-mutant colorectal cancer, HER2-amplified colorectal cancer, KRAS G12C-mutant colorectal cancer, Anal cancer (squamous cell carcinoma), Appendiceal cancer and pseudomyxoma peritonei, Small intestine cancer (small bowel adenocarcinoma), Small intestinal neuroendocrine tumours, Anal high-grade squamous intraepithelial lesions (precursor), Localised anal squamous cell carcinoma (stage I to III), Metastatic and recurrent anal squamous cell carcinoma, Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei, Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell), Goblet cell adenocarcinoma of the appendix, Localised small bowel adenocarcinoma (stage I to III, resected), Advanced and metastatic small bowel adenocarcinoma
Background: Faecal immunochemical test (FIT). Also on OnCo: Symptoms and red flags · Early detection roadmap.
Average-risk screening from age 45 (colonoscopy, faecal immunochemical test, stool DNA or blood test); earlier and more frequent colonoscopy for family history or a known syndrome; investigate rectal bleeding and iron deficiency promptly at any age.
Germline multigene testing for every patient; mismatch repair, RAS, BRAF and HER2 testing; fertility counselling before treatment.
As for colorectal and rectal cancer by stage: surgery, adjuvant FOLFOX or CAPOX for stage III, total neoadjuvant therapy or organ preservation for rectal tumours; no escalation on the basis of age alone.
Genotype-directed therapy as for all metastatic colorectal cancer: checkpoint blockade if mismatch-repair deficient, encorafenib-cetuximab for BRAF V600E, HER2 or KRAS G12C combinations, otherwise chemotherapy with bevacizumab or an anti-EGFR antibody by sidedness.
Structured exercise (CHALLENGE), long-term neuropathy and bowel function care, fertility and sexual health follow-up, financial and employment support.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
If a childhood exposure to colibactin-producing Escherichia coli writes APC mutations into the colon decades before a tumour appears, then the rise in early-onset bowel cancer may be preventable by something done in childhood rather than by screening alone.
The numbers behind the argument that the screening programme is working for the people it covers and failing everyone below its start age; the stage shift going into reverse is the most uncomfortable figure on this roadmap.
The early-onset colorectal cancer page's emphasis on investigating rectal bleeding at any age, universal germline testing and avoiding treatment escalation on age alone follows this framing.
One of the few modifiable exposures with a plausible adolescent window to match the birth-cohort pattern; it is the kind of hypothesis a cohort can generate but not settle.
Screening from 45 is now standard in the United States and has been adopted or debated elsewhere; it is the main policy response to early-onset colorectal cancer.
The European counterpart to Siegel 2017, and the evidence a UK screening age extension has to be argued against: the fastest relative rise is in people two decades below any screening programme's start age.
The paper that turned early-onset colorectal cancer from an anecdote into a policy problem, and the direct evidence behind lowering the screening start age from 50 to 45 in the United States.
The CMS framework organises colorectal cancer biology and trial stratification; BRAF V600E tumours cluster in CMS1, and CMS4's shorter survival and stromal signalling are targets of ongoing research.
Query for this cancer: (TITLE:"Early-onset colorectal cancer" OR ABSTRACT:"Early-onset colorectal cancer" OR TITLE:"under 50" OR ABSTRACT:"under 50" OR TITLE:"Young-onset colorectal cancer" OR ABSTRACT:"Young-onset colorectal cancer" OR TITLE:"Colorectal cancer in adults under 50" OR ABSTRACT:"Colorectal cancer in adults under 50" OR TITLE:"Early-age-onset colorectal cancer" OR ABSTRACT:"Early-age-onset colorectal cancer" OR TITLE:"Bowel cancer in young adults" OR ABSTRACT:"Bowel cancer in young adults") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Early-onset colorectal cancer (under 50), not a curated reading list.
The targets of this cancer's medicines and the ones linked to it directly.
Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Fainting, near-fainting, or an irregular or racing heartbeat; several kinase inhibitors prolong the QT interval and the labels require ECG and electrolyte monitoring.
Bleeding that does not stop by itself, bleeding from more than one site, or new bruising in several places or one large area.
Sudden severe abdominal pain, a hard or very tender abdomen, or abdominal pain with vomiting and fever. Boxed warning for gastrointestinal perforation on bevacizumab.
Persistent headache with extreme tiredness, nausea, dizziness on standing or low blood pressure. Vomiting, severe weakness or collapse is adrenal crisis.
CYP3A4: Tucatinib (strong inhibitor) raises Encorafenib exposure (sensitive substrate).. Avoid strong and moderate inhibitors; if unavoidable, reduce to one-third (strong) or one-half (moderate) of the dose.
No pharmacokinetic interactions expected (antibody). See the irAE guide for toxicity management.
See all on the product pages:BevacizumabCAPOX (capecitabine, oxaliplatin)EncorafenibFOLFOX (5-FU, leucovorin, oxaliplatin)PembrolizumabSotorasibTucatinib·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with Early-onset colorectal cancer, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.